Clinic Roundup

 Apogenix GmbH, of Heidelberg, Germany, said the Phase II trial of lead compound APG101 met its primary endpoint of six-month rate of progression-free survival (PFS) in second-line treatment of glioblastoma multiforme. APG101 is a fully human fusion protein combining the extracellular domain of the CD95 receptor and the Fc portion of IgG. In the randomized, open-label trial, 83 patients were treated with APG101 and radiotherapy or with radiotherapy alone.